PTPA and thymus lymphoma: There are various pharmacological drugs that target PP2A and are applied to embryonic stem cell pluripotency, cell viability, and cancer therapy,[32] raising the possibility that these compounds might be repurposed to ameliorate thymic lymphoma progression dependent on the PP2A‐ERK axis.